BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Responds to Fentanyl WMD Executive Order, Highlights AVERSA(TM) FENTANYL Development

Nutriband (NASDAQ: NTRB) said the Trump Administration Executive Order designating illicit fentanyl and its core precursor chemicals as weapons of mass destruction should not be conflated with “FDA”-approved prescription fentanyl therapies such as transdermal fentanyl patches, which it said are produced under rigorous regulatory oversight and remain medically necessary for certain severe chronic pain patients. The White House+1 The company noted ongoing concerns around transdermal fentanyl patch abuse and accidental pediatric exposure and said it is partnering with Kindeva to develop AVERSA(TM) FENTANYL, which combines Nutriband AVERSA(TM) abuse-deterrent technology with Kindeva FDA-approved fentanyl patch to deter abuse and reduce accidental exposure while maintaining access for patients who need prescription fentanyl products. Nutriband said AVERSA(TM) FENTANYL could be the first abuse-deterrent opioid patch and has the potential to reach peak annual U.S. sales of $80 million to $200 million, with an initial focus on the U.S. market and a stated goal of broader availability in major global medical markets.

To view the full press release, visit https://ibn.fm/hcV7T

About Nutriband Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA(TM) abuse-deterrent technology. AVERSA(TM) technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company’s website is www.nutriband.com . Any material contained in or derived from the Company’s websites or any other website is not part of this press release.

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN